BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Suvoda Enhances IRT for Precise Clinical Trial Drug Supply

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...

October 12, 2023 | News

CanariaBio and Hikma Sign Oregovomab Distribution and License Deal for MENA Region

"We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations," said&n...

October 11, 2023 | News

CANbridge's CAN108 (LIVMARLI®) Receives Approval in Taiwan for ALGS-Related Pruritus

CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ...

October 09, 2023 | News

Innovent Initiates Phase 3 Study of Efdamrofusp Alfa for Age-related Macular Degeneration

nnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 09, 2023 | News

Veramed expands its global footprint by acquiring Clinical Trial Data Services (CTDS)

Specialist Biometrics CRO, Veramed, announced the acquisition of Boston-based data management, biostatistics and medical writing company, CTDS. The d...

October 06, 2023 | News

Emmes acquires VaxTRIALS

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical inn...

October 06, 2023 | News

FDA Grants Orphan Drug Status to GC Biopharma's Thrombocytopenic Purpura Drug in South Korea

When designated as an orphan drug, there are incentives such as tax credits for clinical development costs and exemptions from PDUFA user fees Initial Pedi...

October 06, 2023 | News

Everest Medicines' Partner Calliditas Shares NefIgArd Phase 3 Trial Data at ISIN Tokyo 2023

"The positive findings from biomarker and patient subgroup analyses from the Phase 3 NefIgArd study highlights that Nefecon® treatment results in ...

October 05, 2023 | News

Australia's First Cu-67 SAR-Bombesin Prostate Cancer Trial Patient Treated

COMBAT, which derives from "Copper-67 SAR-Bombesin in metastatic castrate resistant prostate cancer (NCT05633160)1 is a dose escalation and co...

October 04, 2023 | News

Akeso and RemeGen Team Up for Gastric Cancer Therapy Study

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...

October 02, 2023 | News

Bionomics Reports Positive Phase 2b Results for BNC210 in Post-Traumatic Stress Disorder Trial

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. St...

September 29, 2023 | News

Hong Kong's Akeso Receives FDA IND Clearance for AK117 in MDS Combo with Azacitidine

The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States. Based on th...

September 29, 2023 | News

Mabwell Starts Phase Ib/II Trial for Nectin-4 ADC with PD-1 Inhibitor

The clinical trial (CTR20232677) is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 9MW2821 in combination with ...

September 29, 2023 | News

OBiO Launches GMP Facility Intelli-M for Rapid Delivery of Innovative Therapies

The launch of the new base in Shanghai will enhance OBiO's production and service capabilities in both China and the United States...

September 28, 2023 | News

Stay Connected